Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
These practice guidelines for the biological treatment of alcohol use disorders are an update of the first edition, published in 2008, which was developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). For this 2016 revision, we performed a systematic review (MEDLINE/PUBMED database, Cochrane Library) of all available publications pertaining to the biological treatment of alcoholism and extracted data from national guidelines. The Task Force evaluated the identified literature with respect to the strength of evidence for the efficacy of each medication and subsequently categorised it into six levels of evidence (A-F) and five levels of recommendation (1-5). Thus, the current guidelines provide a clinically and scientifically relevant, evidence-based update of our earlier recommendations. These guidelines are intended for use by clinicians and practitioners who evaluate and treat people with alcohol use disorders and are primarily concerned with the biological treatment of adults with such disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 1×
“…disorder with lifetime prevalence estimates of up to 10% globally and 7–10% in most Western countries (Grant et al. 2004; Kessler et al. 2005; Pirkola et al. 2006; Hasin et al. 2007), although one study found clear evidence for high variability in 12-month prevalence rates (Rehm et al. 2005).”
BackgroundGrant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556 · cited 1×
“…from the United States suggest that the 12-month and lifetime prevalence of alcohol use disorder (AUD) is 13.9 and 29.1%, respectively (using criteria of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5; American Psychiatric Association 2013)) (Grant et al. 2015).”
MethodInfluentialKessler, R. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830160031005 · Cited by 2,085
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“The most frequently used measure of alcohol withdrawal severity is the Clinical Institute Withdrawal Assessment–Alcohol, revised (CIWA-Ar, Sullivan et al. 1989) scale.”
MethodWhiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116820 · Cited by 1,175 · cited 1×
“…heavy-drinking episodes may have a beneficial effect on the risk of ischaemic heart disease (Roerecke & Rehm 2014), the effect is far outweighed by the substantial psychiatric, somatic, social and economic burden caused by AUDs (Connor et al. 2015; Schoepf & Heun 2015; Whiteford et al. 2015).”
BackgroundThe relation between different dimensions of alcohol consumption and burden of disease: an overview
Rehm, J., Baliunas, D., Borges, G. L. G., Graham, K., Irving, H., Kehoe, T., Parry, C. D., Patra, J., Popova, S., Poznyak, V., et al. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02899.x · Cited by 1,174 · cited 1×
“Individuals with an AUD also show an excess mortality rate (Rehm et al. 2010; Laramee et al. 2013; Roerecke & Rehm 2013).”
BackgroundReward-motivated learning: mesolimbic activation precedes memory formation
Adcock, R. A., Thangavel, A., Whitfield-Gabrieli, S., Knutson, B., & Gabrieli, J. D. E. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.036 · Cited by 977
Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0211 · Cited by 934 · cited 1×
“There is a lifetime prevalence of 6–20% for anxiety disorders among alcohol-dependent individuals, with social and specific phobias having the highest risk (Kessler et al. 1997; Grant et al. 2005; Conway et al. 2006).”
BackgroundJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 4×
“Findings from recent meta-analyses (Maisel et al. 2013; Jonas et al. 2014; Donoghue et al. 2015) on the efficacy of anti-craving drugs were also incorporated.”
BackgroundInfluentialOral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Magill, M., & Ray, L. A. (2009) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2009.70.516 · Cited by 694
Edenberg, H. J., Dick, D. M., Xuei, X., Tian, H., Almasy, L., Bauer, L. O., Crowe, R. R., Goate, A., Hesselbrock, V., Jones, K., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383283 · Cited by 655
Self-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Self-citationThe clock gene Per2 influences the glutamatergic system and modulates alcohol consumption
Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1163 · Cited by 594 · cited 1×
“Acamprosate has been shown to reduce brain glutamate levels and alcohol consumption in mice that are mutated for the Per2 gene (Spanagel et al. 2005).”
BackgroundOslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571 · cited 1×
“In some naltrexone studies, for example, carriers of a variant (118G or Asp40) allele in OPRM1, which encodes the l-opioid receptor, had better treatment responses to naltrexone than did 118A (or Asn40) allele homozygotes (Oslin et al. 2003; Anton 2008).”
BackgroundSelf-citationTopiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Cognitive therapy: Past, present, and future
Beck, A. T. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.2.194 · Cited by 513
The prevalence and impact of alcohol problems in major depression: A systematic review
Sullivan, L. E., Fiellin, D. A., & O’Connor, P. G. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.01.007 · Cited by 489
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444 · cited 3×
“A number of clinical studies of the efficacy of disulfiram in treating alcohol dependence have been conducted but there has been little consistency in the findings (Fuller et al. 1986; Hughes & Cook 1997; Garbutt et al. 1999; Krampe et al. 2006) (Level C).”
BackgroundResultMayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434 · cited 3×
“Many clinicians favour the longer-acting agents because they provide a smoother course of withdrawal, may require less frequent dosing and are more forgiving of a missed dose (Mayo-Smith 1997).”
BackgroundPharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence
Walker, B. M., & Koob, G. F. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301438 · Cited by 392 · cited 1×
“The function of the kappa receptor is not entirely clear, but it may be relevant to the motivational aspects of alcoholism (Walker & Koob 2008; Walker et al. 2012; Walker et al. 2011).”
BackgroundConnor, J. P., Haber, P. S., & Hall, W. D. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00122-1 · Cited by 389
The Status of Disulfiram: A Half of a Century Later
Suh, J. J., Pettinati, H. M., Kampman, K. M., & O'Brien, C. P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222512.25649.08 · Cited by 382 · cited 6×
“However, at present, this treatment cannot be recommended (Suh et al. 2006).”
BackgroundInfluentialDisulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347 · cited 2×
“number of days drinking, time to first relapse) in a total of 22 RCTs found a significant overall effect for disulfiram (Skinner et al. 2014).”
BackgroundAlcoholics Anonymous and other 12-step programmes for alcohol dependence
Ferri, M., Amato, L., & Davoli, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005032.pub2 · Cited by 347 · cited 3×
“trials of AA participation, a meta-analysis of studies in patients with AUDs reported similar outcomes for AA participation as other psychosocial interventions or 12-step approaches (Ferri et al. 2006).”
BackgroundResultGabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340 · cited 1×
“Mason et al. (2014), in a 12-week dose-ranging RCT of oral gabapentin (dosages of 0 (placebo), 900mg/day or 1800mg/day; n¼ 150, concomitant manual-guided counselling), found that gabapentin significantly improved the rates of abstinence and ‘no heavy drinking’.”
BackgroundLingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332 · cited 1×
“The British Association for Psychopharmacology guidelines recommend that a dose of >500mg of thiamine should be given for 3–5 days if WKS is suspected or the diagnosis is established (Lingford-Hughes et al. 2012).”
BackgroundAlcohol use disorders and mortality: a systematic review and meta-analysis
Roerecke, M., & Rehm, J. (2013) · Addiction · doi:10.1111/add.12231 · Cited by 326
Effect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 4×
“…aid, has been evaluated in a number of clinical trials for its efficacy in AUD treatment (McKee et al. 2009; Fucito et al. 2011; Hays et al. 2011; Childs et al. 2012; Mitchell et al. 2012; Litten et al. 2013; Meszaros et al. 2013; Plebani et al. 2013) (for a review see Erwin & Slaton 2014).”
BackgroundInfluentialRiper, H., Andersson, G., Hunter, S. B., Wit, J., Berking, M., & Cuijpers, P. (2014) · Addiction · doi:10.1111/add.12441 · Cited by 276 · cited 1×
“A more recent meta-analysis of 12 studies found a small but clinically significant effect of combined CBT/MI treatment compared with treatment as usual (Riper et al. 2014).”
ResultAllelic and haplotypic association of GABRA2 with alcohol dependence
Covault, J., Gelernter, J., Hesselbrock, V., Nellissery, M., & Kranzler, H. R. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30091 · Cited by 273 · cited 1×
“Recent genetic studies also show that vulnerability to alcoholism may be mediated in part through variation in the genes encoding GABA receptor subunits (Covault et al. 2004; Dick et al. 2004; Edenberg et al. 2004; Lappalainen et al. 2005; Fehr et al. 2006; Soyka et al. 2008b).”
BackgroundSalloum, I. M., Cornelius, J. R., Daley, D. C., Kirisci, L., Himmelhoch, J. M., & Thase, M. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.37 · Cited by 271
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence
Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C., & Cutler, R. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.719 · Cited by 271
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal
Myrick, H., Malcolm, R., Randall, P. K., Boyle, E., Anton, R. F., Becker, H. C., & Randall, C. L. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00986.x · Cited by 201 · cited 1×
“Gabapentin in higher doses was found to be as clinically effective as lorazepam (Myrick et al. 1998; Myrick et al. 2009) (see 3.5 ‘Anticonvulsants’ below).”
BackgroundInfluentialBauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199 · cited 1×
“In general, the same guidelines can be used for the biological treatment of affective disorders in alcoholdependent patients as for non-alcohol-dependent patients (for WFSBP guidelines see Bauer et al. 2013; Bauer et al. 2015), although a few special considerations are warranted.”
BackgroundSelf-citationThe COMBINE Study Research Group (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2003.tb02873.x · Cited by 174
The efficacy of disulfiram: a review of outcome studies
HUGHES, J. C., & COOK, C. C. H. (1997) · Addiction · doi:10.1111/j.1360-0443.1997.tb03370.x · Cited by 162
Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond
Sachdeva, A. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/13407.6538 · Cited by 141
A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence
DE SOUSA, A., & DE SOUSA, A. (2004) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh104 · Cited by 108
An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence
DE SOUSA, A., & DE SOUSA, A. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh187 · Cited by 107
Schmidt, C. S., Schulte, B., Seo, H., Kuhn, S., O'Donnell, A., Kriston, L., Verthein, U., & Reimer, J. (2016) · Addiction · doi:10.1111/add.13263 · Cited by 107 · cited 1×
“However, results from randomised trials show mixed results for the efficacy of screening and brief interventions in primary and inpatient care and emergency departments (Substance Abuse and Mental Health Services Administration 1999; Schmidt et al. 2015).”
ResultMishra, B. R., Praharaj, S. K., Katshu, M. Z. U. H., Sarkar, S., & Nizamie, S. H. (2015) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.13010013 · Cited by 89 · cited 1×
“…seven studies have investigated rTMS in patients with alcohol dependence (Mishra et al. 2010; Hoppner et al. 2011; Herremans et al. 2012; Rapinesi et al. 2014; Ceccanti et al. 2015; Girardi et al. 2015; Mishra et al. 2015), with some suggesting efficacy, particularly in the reduction of craving.”
BackgroundStedman, M., Pettinati, H. M., Brown, E. S., Kotz, M., Calabrese, J. R., & Raines, S. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01270.x · Cited by 70
Cortico-striatal circuits: novel therapeutic targets for substance use disorders
Kravitz, A. V., Tomasi, D., LeBlanc, K. H., Baler, R., Volkow, N. D., Bonci, A., & Ferré, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.03.048 · Cited by 63
Brown, E. S., Davila, D., Nakamura, A., Carmody, T. J., Rush, A. J., Lo, A., Holmes, T., Adinoff, B., Caetano, R., Swann, A. C., et al. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12445 · Cited by 50 · cited 1×
“A subsequent randomised, double-blind, placebo-controlled study of quetiapine for treatment of bipolar disorder, mixed or depressive phase, showed no effect of the active medication on alcohol consumption (Brown et al. 2014).”
BackgroundLikhitsathian, S., Uttawichai, K., Booncharoen, H., Wittayanookulluk, A., Angkurawaranon, C., & Srisurapanont, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.06.032 · Cited by 46 · cited 1×
“Likhitsathian et al. (2013) conducted a 12-week RCT in 106 alcohol-dependent outpatients.”
Method
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Carvalho, A. F., Heilig, M., Perez, A., Probst, C., & Rehm, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31775-1 · Cited by 671
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000668 · Cited by 185
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Metadata
- Authors
- Soyka, M., Kranzler, H. R., Hesselbrock, V., Kasper, S., Mutschler, J., Möller, H.-J., & The WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2016-12-23
- Volume
- 18
- Issue
- 2
- Pages
- 86-119
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2565728627
- Cited by
- 85
- References
- 48
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.